key: cord-0725795-7ubx0r5u
authors: Zangrillo, Alberto; Landoni, Giovanni; Monti, Giacomo; Yavorovskiy, Andrey G; Redaelli, Martina Baiardo
title: Dexametasona en COVID-19: ¿un medicamento para todos?
date: 2021-04-19
journal: Med Intensiva
DOI: 10.1016/j.medin.2021.03.008
sha: 3b9f5fac3efb9dbe3fdb5781fe9b090e1416fdee
doc_id: 725795
cord_uid: 7ubx0r5u

nan

The COVID-19 pandemic challenged clinicians worldwide to treat a new and unknown disease. With more than 95 million confirmed cases since its beginning 1 , a lot of effort has been made to identify the best possible treatments.

The RECOVERY trial 2 provides strong evidence in favor of the administration of 6mg of dexamethasone for ten days once a day in COVID-19 patients, if requiring at least oxygen supplementation (the incidence of death in the dexamethasone group compared to the usual care group was 23.3% vs 26.2% for patients receiving oxygen, and 29.3% vs 41.4% for patients under mechanical ventilation at the time of randomization). This finding changed the WHO therapeutic guidelines for patients with COVID-19 3 and triggered into clinicians the automatic binomial prescription: oxygen therapy-dexamethasone. In the current pandemic era, where everyone is searching for the magic bullet, and no clear evidence is available on any therapeutic agent capable to reduce mortality, having this option with such a familiar drug gave back to clinicians the feeling of having at least a weapon.

The trial findings were confirmed also in a recent meta-analysis 4 including more than seven thousand patients: overall mortality was significantly lower in the corticosteroids group (26% vs 28%, relative risk {RR} The rationale for the use of dexamethasone is the mitigation of the inflammatory organ injury that may occur during SARS-CoV-2 infection. In the RECOVERY Trial the benefit of dexamethasone was indeed clear when inflammatory lung damage was more likely to be common, that is supposed to be in those patients treated "more than 7 days after symptom onset". However, as mentioned by the authors of the trial, only a subgroup of severe COVID-19 patients showed significant elevation in inflammatory biomarkers (such as C-reactive protein and ferritin), and unfortunately the "inflammatory lung damage" was advocated but not assessed.

Beside the desired anti-inflammatory effect, dexamethasone is also known for its immunosuppressive properties, that can lower resistance to bacterial and viral infections through a cell-mediated mechanism. Furthermore, as well as corticosteroids increase mortality in patients not requiring oxygen therapy 4 , it is reasonable to think that their effect among patients requiring low flow oxygen could be mixed. As in a previous study 6 that identified two different subphenotypes of acute respiratory distress syndrome, one of which was categorised by more severe inflammation, it is likely that also in COVID-19 patients different inflammatory patterns may occur. In support to this previous finding, a recent review and meta-analysis of COVID-19 studies focused on the role of cytokines and inflammatory biomarkers and found different mean levels of C-reactive protein between severe and critical COVID-19 patients (55.9 μg/mL [CI 23.1-88.8μg/mL

Beyond the initial enthusiasm after the trial results, leading to an almost indiscriminate adoption of dexamethasone in COVID-19 patients, we suggest that a more personalized prescription would lead to further improvements in patients' outcome. We think that, beside avoiding corticosteroids for patients not on oxygen, COVID-19 patients requiring oxygen should be screened for high or normal inflammatory biomarkers thresholds. Furthermore, for those patients who may benefit from corticosteroid treatment it is reasonable to investigate whether a higher or a lower dose of dexamethasone is most beneficial, and a clinical trial is currently ongoing randomising patients with severe hypoxia to receive either 6 or 12mg of dexamethasone.

This would serve to target inflammation only in those patients who would probably benefit from its modulation, while removing the burden of corticosteroids side effects in those patients without an inflammatory pattern who would probably not benefit from this therapy.

WHO Coronavirus Disease (COVID-19) Dashboard

Dexamethasone in Hospitalized Patients with Covid-19

Therapeutic Management | COVID-19 Treatment Guidelines

Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia (COVIDSTEROID2)